Science Explorer Back to mapMap
Discussion
Researcher · Mundipharma (United Kingdom) · United Kingdom

Thomas Mehrling

Thomas Mehrling publishes mostly in Molecular Biology, Oncology and Hematology, on topics such as Histone Deacetylase Inhibitors Research, Multiple Myeloma Research and Treatments and Protein Degradation and Inhibitors.

ORCID 0000-0003-0295-0299 OpenAlex
World rank
#4,721,215
of 7,710,434 ranked researchers
Rank in United Kingdom
#289,130
of 367,258
Works
40
Citations
445
Citations per work
11.1
h-index
10
i10-index 10Top 76% in Molecular Biology
Thomas Mehrling

What does Thomas Mehrling research?

Thomas Mehrling's work is mostly in Medicine (44%), Biochemistry, Genetics and Molecular Biology (36%).

Health Sciences: 18 works · 43.8% of their workMedicine: 18 works · 43.8% of their workOncology: 6 works · 14.9% of their workHematology: 5 works · 11.4% of their workGenetics: 4 works · 9.6% of their workPathology and Forensic Medicine: 2 works · 4.4% of their workEpidemiology: 1 works · 3.5% of their workLife Sciences: 14 works · 36.0% of their workBiochemistry, Genetics and Molecular Biology: 14 works · 36.0% of their workMolecular Biology: 14 works · 36.0% of their workEverything else: 8 works · 20.2% of their workTHEIR WORKThomas Mehrling40works
Life Sciences36%Health Sciences44%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine1843.8%
    1. Biochemistry, Genetics and Molecular Biology1436.0%
  3. Everything else820.2%
  1. 1Molecular Biology36% of their works
  2. 2Oncology15% of their works
  3. 3Hematology11% of their works
  4. 4Genetics10% of their works
  5. 5Pathology and Forensic Medicine4% of their works
  6. 6Epidemiology4% of their works

Research topics

Which keywords describe Thomas Mehrling's research?

The keywords of their largest research topics: HDAC Inhibitors, Histone Deacetylases, Prognostic Factors, Rituximab, Diagnosis Criteria, International Myeloma Working Group, BET Bromodomains and PROTACs.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 18 words, with their numbers
  1. HDAC Inhibitors181 topic
  2. Histone Deacetylases181 topic
  3. Prognostic Factors102 topics
  4. Rituximab102 topics
  5. Diagnosis Criteria81 topic
  6. International Myeloma Working Group81 topic
  7. BET Bromodomains71 topic
  8. PROTACs71 topic
  9. Glioblastoma61 topic
  10. Temozolomide61 topic
  11. AML51 topic
  12. Acute Myeloid Leukemia51 topic
  13. Chronic Lymphocytic Leukemia51 topic
  14. Classification51 topic
  15. Enzyme Regulation51 topic
  16. Genomic Aberrations51 topic
  17. Lymphoma51 topic
  18. Nucleotide Metabolism51 topic

Where does Thomas Mehrling work?

Thomas Mehrling's main affiliation in the publication record is Mundipharma (United Kingdom), United Kingdom.

How many publications and citations does Thomas Mehrling have?

OpenAlex counts 40 works and 445 citations for Thomas Mehrling, an h-index of 10, ranking #4,721,215 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Thomas Mehrling. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.